miR-146a-5p
rnamiR-146a-5p regulates inflammatory cytokine signaling during acute coronary syndromes, enabling ACS detection via plaque inflammation.
Pathway placement
Cascade stepPlaque inflammation
Confidencemedium
RationaleACS detection; modulates inflammatory NF-κB signaling.
Also acts inMyocardial injury
Druggability
Not assessed (no mapped human gene target).
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I20
C — confounder / Type-II57
A — assay feasibility50
E — evidence strength21
T1DI (composite)3
Specificity differential (R−C)-36.8
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Whole blood or cell-free plasma
Collection tube
PAXgene/Tempus RNA tube · K2/K3-EDTA (lavender-top)
Method / principle
RT-qPCR (TaqMan) or small-RNA sequencing
Reagent / substrate
Target-specific primers/probe; reverse transcriptase (miRNA: stem-loop RT primer)
Platform
qPCR instrument / NGS
Turnaround · availability
Research / send-out · Research (few LDTs)
Literature evidence(1)
- Discriminatory power of a circulating multi-noncoding RNA panel in acute coronary syndrome subtypes: Towards precision detection.The international journal of biochemistry & cell biology · 2024 · PMID 38280541 · doi